Ketamine for Treatment-Resistant Bipolar Depression: Stratify, Monitor, Maintain
This commentary reframes real-world ketamine infusion data for treatment-resistant bipolar depression around three practical gaps: patient selection, cognitive monitoring, and relapse prevention.
📅 Journal publication: Sep 2026·Last updated: Oct 12, 2026
Ketamine infusions may offer rapid relief in TRBPD but need tailored maintenance plans.
The study explores ketamine's potential benefits and limitations for treatment-resistant bipolar depression (TRBPD), informing safer and more effective use. Repeated ketamine infusions may improve depressive symptoms rapidly with acceptable short-term safety, but relapse risk requires individualized maintenance strategies. While promising, the variability in inflammatory markers and relapse risk underscores the need for more bipolar-specific research to guide clinical application. Effective TRBPD management with ketamine requires personalized continuation strategies and more research on long-term outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.